Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.60 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.60 |
| ▸ | HTR2C | P28335 | 2/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 6/20 | 0.40 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.39 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.39 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1057454 | 0.87 | SLC6A2 (0.60) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL1057456 | 0.87 | SLC6A2 (0.60) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL935461 | 0.85 | SLC6A4 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL934674 | 0.85 | SLC6A4 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL934702 | 0.85 | SLC6A4 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL934704 | 0.85 | SLC6A4 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL934676 | 0.85 | SLC6A4 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3 | |
| SCHEMBL9108522 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3KCNK2 | |
| SCHEMBL9108520 | 0.84 | SLC6A2 (0.58) | SLC6A2SLC6A4HTR2CSLC6A3KCNK2 | |
| SCHEMBL1059827 | 0.83 | SLC6A2 (0.59) | SLC6A2SLC6A4HTR2CSLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637568-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2013-11-07 | — | — | US | disclosed |
| US-8501964-B2 | Serotonin reuptake inhibitors | THERAVANCE, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | THERAVANCE, INC. (US) | 2012-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142689-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | SLC6A2 2/4885SLC6A4 1/4885HTR2C 13/4885 |
| US-20130296322-A1 | SEROTONIN REUPTAKE INHIBITORS | SLC6A4, SLC6A2, TPH1 | SLC6A2 2/4885SLC6A4 1/4885HTR2C 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.